Antineutrophilic cytoplasmic antibody-associated vasculitis and the kidney

Research output: Contribution to journalReview articlepeer-review


Purpose of reviewThe purpose of this review is to highlight recent studies that have emerged on the topic of ANCA-associated vasculitis with some historical context. The review also discusses how the adult data is relevant to pediatric patients.Recent findingsPediatric studies on AAV are lacking. Therapies targeted to the inflammatory cascade specifically implicated in AAV, such as MPO inhibitors and complement mediators, are emerging. The PEXIVAS study recently called into question the routine use of plasma exchange (PLEX) in severe AAV, with no difference in ESKD or mortality found between patients who did or did not receive PLEX. Longer maintenance duration of nearly 48 months is preferred as compared with shorter duration in patients who are not on dialysis because of higher relapse rates in children with AAV.SummaryCurrent treatment in AAV includes corticosteroids, rituximab, and cyclophosphamide for induction. Maintenance therapy commonly consists of azathioprine or rituximab. Plasma exchange (PLEX) is no longer recommended for induction therapy for AAV but some experts still consider this as an option for patients who are not responding to therapy or have severe disease at presentation. However, emerging novel therapies may be on the horizon.

Original languageEnglish (US)
Pages (from-to)197-202
Number of pages6
JournalCurrent Opinion in Pediatrics
Issue number2
StatePublished - Apr 1 2022

Bibliographical note

Publisher Copyright:
© 2022 Lippincott Williams and Wilkins. All rights reserved.


  • antineutrophilic cytoplasmic antibody-associated vasculitis
  • pediatric glomerulonephritis
  • plasma exchange

PubMed: MeSH publication types

  • Journal Article
  • Review


Dive into the research topics of 'Antineutrophilic cytoplasmic antibody-associated vasculitis and the kidney'. Together they form a unique fingerprint.

Cite this